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Keratinocytesare critical regulatory proteins that function in replication, genome segregation,
and viral transcription, including control of expression of the viral oncogenes, E6 and E7. Sumoylation is a
post-translational modiﬁcation that has been shown to target and modulate the function of many
transcription factors, and we now demonstrate that E2 proteins are sumoylated. Both bovine and human
papillomavirus E2 proteins bind to the SUMO conjugation enzyme, Ubc9, and using in vitro and E. coli
sumoylation systems, these E2 proteins were readily modiﬁed by SUMO proteins. In vivo experiments further
conﬁrmed that E2 can be sumoylated by SUMO1, SUMO2, or SUMO3. Mapping studies identiﬁed lysine 292 as
the principal residue for covalent conjugation of SUMO to HPV16 E2, and a lysine 292 to arginine mutant
showed defects for both transcriptional activation and repression. The expression levels, intracellular
localization, and the DNA-binding activity of HPV16 E2 were unchanged by this K292R mutation, suggesting
that the transcriptional defect reﬂects a functional contribution by sumoylation at this residue. This study
provides evidence that sumoylation has a role in the regulation of papillomavirus E2, and identiﬁes a new
mechanism for the modulation of E2 function at the post-translational level.
© 2008 Elsevier Inc. All rights reserved.IntroductionHuman papillomavirus (HPV) infects both genital and cutaneous
epithelium, and high risk HPV is the causative agent in cervical cancer.
The E2 early protein is a key regulatory protein that functions in viral
replication (Chiang et al., 1992; Demeret et al., 1995; Stubenrauch et
al., 1998), genome segregation (McPhillips et al., 2006; You et al.,
2004), and transcriptional control (Demeret et al., 1997; Kovelman et
al., 1996). E2 binds to multiple sites in the upstream regulatory region
(URR) and regulates early promoter expression in both a positive (low
E2 concentration) and negative (high E2 concentration) fashion
(Demeret et al., 1997). E2 also interacts with several cellular factors
such as Sp1 (Steger et al, 2002), YY1 (Lee et al, 1998), C/EBP (Hadaschik
et al., 2003), and Brd4 (Baxter et al., 2005; You et al., 2004), and these
interactions further contribute to viral and cellular transcriptional
activity.
The life cycle of HPVs is closely linked to the epithelial differentia-
tion scheme of the infected host keratinocyte (Longworth and
Laimins, 2004), and BPV1 E2 was found to accumulate and be more
stabilized in the stratum spinosum (Penrose andMcBride, 2000). Such
differentiation-dependent changes in E2 levels likely provide some
control of E2 transcriptional activity during the virus life cycle.
Alternatively, the activity of many transcription factors is regulated by
post-translational modiﬁcations, but this type of control has not beenilson).
l rights reserved.examined thoroughly for E2 proteins. A recent study showed that
overall sumoylation was upregulated during keratinocyte differentia-
tion (Deyrieux et al., 2007), suggesting that this modiﬁcationmight be
globally coordinating transcription and could also be relevant to E2
activity.
Sumoylation is a post-translational modiﬁcation, prevalent among
transcription factors, where the small ubiquitin-related modiﬁer
(SUMO) is attached to the substrate proteins in a reversible manner
(Matunis et al., 1996). There are three principle SUMO proteins:
SUMO1, SUMO2, and SUMO3. SUMO 2 and 3 are 98% identical and
form a distinct group from SUMO1 with whom they share only ∼50%
identity. The process and enzymes involved in sumoylation are
functionally similar to those enzymes catalyzing the attachment of
ubiquitin to its substrates (Hay, 2005). Sumoylation occurs in multiple
steps with SUMO ﬁrst attached to the heterodimeric activating
enzyme, SAE1/SAE2, in an ATP-dependent fashion. Next, the activated
SUMO is covalently transferred to Ubc9, the SUMO-speciﬁc conjugat-
ing enzyme (Desterro et al., 1999). The ﬁnal transfer of SUMO from
Ubc9 to the substrate can occur directly, but is enhanced by SUMO
ligases such as the PIAS family proteins (Schmidt and Muller, 2003).
Addition of SUMO occurs exclusively at lysine residues, most
commonly in the acceptor motif ΨKx(E/D) where Ψ is a large
hydrophobic amino acid, K is the target lysine, x is any amino acid,
and the fourth position (E/D) is either glutamic or aspartic acid. SUMO
attached to the substrate lysine can be speciﬁcally cleaved by SUMO
proteases (SENPs), making this a dynamic process of modiﬁcation/
demodiﬁcation (Mukhopadhyay and Dasso, 2007). Modiﬁcation by
Table 1
Prediction and conservation of sumoylation residues in papillomavirus E2
Residue Sumo probability
BPV1 K111 0.68
HPV6 K111/K112 0.31
HPV11 K111/K112 0.31
HPV16 K111/K112 0.31
HPV18 K115 0.68
HPV31 K111/K112 0.31
BPV1 (Didn't get alignment) K322 0.73
HPV6 K298 0.56
HPV11 K297 0.56
HPV16 K299 –
HPV18 K300 –
HPV31 K306 –
HPV16 K292 0.91
HPV18 K293 0.91
HPV31 K299 0.91
HPV6 K351 0.82
HPV11 K350 0.82
HPV16 K351 0.82
HPV18 A at this position –
HPV31 K358 0.82
330 Y.-C. Wu et al. / Virology 378 (2008) 329–338SUMO is believed to play a role in various cellular processes, including
protein–protein interaction, subcellular localization, and transcrip-
tional regulation (Dohmen, 2004). Sumoylation most commonly
represses transcriptional activity, but examples of transcriptional
activation have also been reported (Goodson et al., 2001; Hong et al.,
2001; Rodriguez et al., 1999; Wei et al, 2007).
Several transcriptional regulatory early proteins of other DNA virus
families, such as Rta of Epstein–Barr virus and K-bZIP of Kaposi's
sarcoma-associated herpesvirus, have been shown to be sumoylated,
and the transcriptional activities of these proteins are modulated by
SUMO modiﬁcation (Chang et al., 2004; Izumiya et al., 2005).
Inspection of E2 protein sequences revealed potential sumoylation
sites implying that this modiﬁcationmay be similarly important for E2
transcriptional activity. In the present study, we demonstrate binding
between Ubc9 and various papillomavirus E2 proteins in vitro,
sumoylation of both BPV1 E2 and HPV18 E2 in vitro and in E. coli,
and in vivo sumoylation of HPV16 E2 at lysine 292. Mutation of lysine
292 to arginine eliminated sumoylation, indicating that this amino
acid was the major sumoylation target site. Furthermore, the
transcriptional activity of the 16E2 lysine 292 to arginine mutantFig. 1. Binding of BPV1 and HPV E2 proteins to Ubc9 in vitro. (A) Radiolabeled HPV18 E2
proteins were incubated with 2 to 8 μg of GST or GST-Ubc9 proteins bound to
glutathione-Sepharose as indicated. Eluted material was analyzed on an SDS-
polyacrylamide gel (10%), and the bound proteins were visualized by autoradiography.
(B) Radiolabeled BPV1 E2, HPV11 E2, or HPV16 E2 proteins were incubated with 8 μg of
GST or GST-Ubc9 proteins bound to glutathione-Sepharose. Eluted material was
analyzed as in (A). The percentage of input protein bound is indicated below the
respective lanes.was reduced compared to the wild-type HPV16 E2 on both an E2-
activated and an E2-repressed promoter. However, the mutant E2
protein was expressed at similar levels as wild-type E2, and neither
the DNA binding activity nor the subcellular localization of E2 was
affected by this mutation, suggesting that the transcriptional defect
was related to the absence of sumoylation.
Results
BPV1 and HPV E2 proteins interact with Ubc9 in vitro
Examination of sequences from several common high-risk and
low-risk HPV E2 proteins revealed that all had high probability sumo-
ylation sites, though no single predicted sumoylation site was well
conserved between the high-risk and low-risk sequences (Table 1).
Nonetheless, the high-risk E2 types all had 2–3 good potential
sumoylation sites, as did BPV1 E2 (not shown), so we focused on the
E2 proteins from HPV16, HPV18, and BPV1 for these studies. Typically,
sumoylated proteins bind directly to the SUMO-speciﬁc conjugating
enzyme, so GST pull-down assays were performed with a bacteriallyFig. 2. In vitro sumoylation of BPV1 and HPV18 E2. (A) In vitro translated and 35S-labeled
BPV1 E2 or HPV18 E2 proteins were incubated in the presence of the various
combinations of puriﬁed sumoylation system proteins as indicated above each lane. For
lanes 1 to 3 in both the upper and lower panels, themixtures were incubated at 30 °C for
90 min. For lane 4 in both panels, the mixtures were ﬁrst incubated at 30 °C for 60 min
without Ulp1. After the 60 min sumoylation reaction, 1 μg of Ulp1 was added and the
reactions were incubated at 30 °C for another 30 min. Final reactions were
electrophoresed on an SDS-polyacrylamide gel (10%) and labeled E2 proteins were
visualized by autoradiography. Note that for BPV E2 the addition of SAE1/2 and Ubc9
without SUMO consistently caused a loss of full-length E2 protein. The mechanism for
this loss has not been investigated. (B) His-tagged 18E2 encoded by pET-18E2 was
introduced into the E. coli BL21(DE3) strain, the pTE1E2S1-BL21(DE3) strain, or the
pTE1E2S2-BL21(DE3) strain to form stable transformants. Cultures of each transformant
were spilt in half, and one half was adjusted to a ﬁnal concentration of 0.5 mM of IPTG
(induced) and the other was left untreated (uninduced). Both the induced and
uninduced cultures were further incubated at 23 °C for 8 h. After collection of cells,
these samples were analyzed by Western blot with anti-His antibodies. For both panels
(A) and (B), the single asterisk (⁎) indicates the unmodiﬁed form of either BPV1 E2 or
HPV18 E2, and the double asterisk (⁎⁎) indicates the sumoylated form.
331Y.-C. Wu et al. / Virology 378 (2008) 329–338expressed GST-Ubc9 fusion protein and 35S-labeled full-length E2
proteins (Fig. 1). An equal amount of 35S-labeled protein was incu-
bated with GST alone or GST-Ubc9 fusion protein bound to
glutathione-Sepharose beads. After washing, the 35S-labeled protein
bound to the beads was extracted and analyzed by autoradiography.
HPV18 E2 associated with GST-Ubc9 in a dose-dependent manner,
but did not interact with GST alone (Fig. 1A). In addition, BPV1 E2,
HPV11 E2, and HPV16 E2 were efﬁciently pulled-down only by GST-
Ubc9 (Fig. 1B). Between 13 and 19% of the input E2 was retained on the
beads, indicating an effective E2-Ubc9 interaction and consistent with
the various E2 proteins being potential targets for sumoylation.
E2 proteins are sumoylated in vitro and in E. coli
To determine if E2 proteins can serve as a substrate for SUMO
modiﬁcation by Ubc9, an in vitro sumoylation system was applied to
BPV1 and HPV18 E2. The E2 proteins were produced by in vitro
translation in the presence of [35S]methionine, and then each was
used as a substrate in the presence or absence of the puriﬁed
sumoylation components. After incubation, the E2 proteins were
analyzed on SDS-polyacrylamide gels and a higherMW form of E2wasFig. 3. Sumoylation of HPV16 E2 by SUMO1, 2, and 3 in vivo. (A) HeLa cells were
transfected with either 3 μg of pWEB-16E2 alone or with a combination of 1.5 μg of
pcDNA5/FRT/TO/His-S-SUMO1, 1.5 μg of pcDNA5/FRT/TO/HA-Ubc9, and 3 μg of pWEB-
16E2. Transfected cells were harvested, extracted, and analyzed by Western blotting as
described in Materials and methods. (B) HeLa cells were transfected with either 3 μg of
pWEB-16E2 alone or with a combination of 1.5 μg of pcDNA3.1/HA-SUMO2 or SUMO3,
1.5 μg of pcDNA5/FRT/TO/HA-Ubc9, and 3 μg of pWEB-16E2. For both (A) and (B), the
parental pcDNA5/FRT/TO vector was used to maintain a constant total DNA amount for
all of the samples. Transfected cells were analyzed as in part (A). (C) HeLa cells were
transfected with a combination of 3 μg of pWEB-16E2, 1 μg of pcDNA3.1/HA-SUMO3,
and 1 μg of pcDNA5/FRT/TO/HA-Ubc9. In each lane, HeLa cells were also transfected
with an additional 1 μg of either pcDNA (lane 1), pEGFP, pEGFP-SENP1, or pEGFP-
SENP1m (C599A) as indicated. For (A), (B), and (C), cells were treated with ALLN one day
post-transfection. Another day after ALLN treatment, total cell lysates were electro-
phoresed on SDS-polyacrylamide gels and the gels were Western blotted with the
antibodies as indicated. The single asterisk (⁎) indicates the unmodiﬁed form of HPV16
E2, the double asterisk (⁎⁎) indicates the monosumoylated form of HPV16 E2, and the
triple asterisk (⁎⁎⁎) indicates di-sumoylated HPV16 E2. In the lower panel of part (C),
EFGP-SENP1 and EFGP-SENP1m are indicated by the arrowhead, and EGFP is indicated
by the arrow.
Fig. 4. Mapping of the sumoylation site in HPV16 E2. (A) Structure and predicted
sumoylation sites in HPV16 E2. The relative locations of the N-terminal transactivation
domain (TAD), the hinge region, and the C-terminal DNA-binding domain (DBD) are as
shown. There are three lysine residues predicted to have a high probability for
sumoylation with the probability of the sumoylation indicated below each residue. (B)
HeLa cells were transfected with a combination of 1.5 μg of pcDNA3.1/HA-SUMO3 and
1.5 μg of pcDNA5/FRT/TO/HA-Ubc9 together with 3 μg of pWEB-16E2 wild-type
(16E2WT, left panel), pWEB-16E2K292R (16E2K292R, left panel), pWEB-16E2K172R
(16E2K172R, left panel), pWEB-16E2K351R (16E2K35 1R, left panel), or pWEB-
16E2K292RK172R (16E2K292RK172R, right panel). Cells were processed as in Fig. 3
and were analyzed by Western blotting with anti-16E2, anti-Ubc9 antibodies, or anti-
tubulin (loading control) as indicated. Ubc9 served as the control for comparing
transfection and expression efﬁciency. The single asterisk (⁎) indicates the unmodiﬁed
form of either HPV16 E2, and the double asterisk (⁎⁎) indicates the sumoylated form.observed for both samples when incubated with the complete
sumoylation components (Fig. 2A). The new E2 species had a MW
increase of ∼15 kDa, which is consistent with the addition of a single
SUMO moiety. Furthermore, the higher MW forms of both the BPV1
and 18E2 proteins were eliminated by treatment with the yeast SUMO
protease, Ulp1, which speciﬁcally cleaves SUMO but not ubiquitin
from proteins (Li and Hochstrasser, 1999). Taken together, these
results show that E2 proteins are substrates for in vitro SUMO
conjugation.
As an alternative to in vitro sumoylation, we also tested HPV18E2
in an E. coli modiﬁcation/expression system that produces SUMO-
conjugated proteins (Uchimura et al., 2004). A His-tagged HPV18 E2
construct was co-expressed with the pTE1E2S1 or pTE2E2S2 plasmids
in E. coli. The pTE1E2S1/S2 plasmids contain a linear fusion of genes
for Aos1 and Uba2 (the SUMO activating enzyme subunits), Ubc9, and
SUMO1 or SUMO2 linked to an IPTG-inducible T7 promoter (Uchimura
et al., 2004). The cultured bacterial lysates expressing 18E2 and/or the
SUMO conjugation system were harvested, and the total cell lysates
were analyzed by Western blotting using anti-His antibody. Without
IPTG induction, only HPV 18E2 was observed in the total cell lysates
(Fig. 2B, left panel). However, eight h after IPTG induction, shifted
bands, around ∼15 kDa larger than the 42 kDa 18E2 band, were ob-
served in the lysates that contained either pTE1E2S1 or pTE1E2S2, but
not in the lysates extracted from cells containing only 18E2 (Fig. 2B,
right panel). In addition, cells co-expressing BPV1 E2 and pTE1E2S1or
S2 also showed sumoylation of BPV1 E2 in E. coli (data not shown).
These results in E. coli are consistent with the in vitro data and indicate
that both BPV1 E2 and HPV18 E2 are effective substrates for either
SUMO1 or SUMO2.
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To determine if E2 is also modiﬁed by SUMO in vivo, HeLa cells
were co-transfected with vectors expressing HPV16 E2, Ubc9, and
either SUMO1, 2, or 3. Because HPV E2 proteins are unstable with
short half-lives, the calpain protease inhibitor, ALLN, was used to
stabilize 16E2 (Penrose and McBride, 2000). 48 h after transfection,
the transfected cells were directly lysed in SDS-sample buffer to
inactivate endogenous SUMO proteases, and the lysates were
analyzed by western blotting with anti-16E2 antibody. As shown
in Fig. 3A, two new bands were seen above the primary E2 band
(∼42 kDa) in the presence of the His-S-SUMO1 plasmid. The band
with the estimated MW of 64 kDa likely corresponds to 16E2 with a
single addition of His-S-SUMO1, while the upper band with the
estimated MW of 86 kDa is likely 16E2 carrying two His-S-SUMO1
proteins. This 86 kDa species could be HPV16 E2 sumoylated at 2
different lysines, but we think this possibility is unlikely based on
the mutational analysis below (Fig. 4). Alternatively, it is known that
the S-tag itself contains a strong potential sumoylation site (Chung
et al., 2004) which could result in His-S-SUMO1-E2 being subse-
quently sumoylated again on the S portion. With either SUMO2 or 3,
a single novel band was visible above the primary E2 band (Fig. 3B),
and its apparent MW (∼60 kDa) was again consistent with
monosumoylation of E2. In addition, to further conﬁrm these novel
E2 species were SUMO-modiﬁed HPV16 E2, a SUMO protease, SENP1,
was co-expressed in HeLa cells together with HPV16 E2, Ubc9, and
SUMO3. The wild-type SENP1 effectively reduced the amount of the
60 kDa band (Fig. 3C, upper panel) while neither EGFP nor a
catalytically inactive SENP1 mutant (SENP1C599A) affected thisFig. 5. HeLa cell colony reduction assay. For this assay, 6×105 HeLa cells were transfected
expressing pcDNA5, 16E2WT, or 16E2K292R. Cells were split 1:3 and grown under G418 selec
and averaged from the three plates for each sample. The upper panel shows one representativ
the average number of colonies from all three experiments.species (Fig. 3C, upper panel). We conclude from these data that
HPV16 E2 is primarily monosumoylated in vivo and can be modiﬁed
by either SUMO1, 2, or 3.
Mapping the E2 sumoylation sites
The studies above indicated that HPV16 E2 was sumoylated at a
single predominant site. To identify the amino acid residue of E2 that
is modiﬁed by SUMO, we generated site-directed mutants of E2 with
lysine to arginine substitutions at key residues based on the predicted
sumoylation sites in E2 (deﬁned with the SUMOplotTM program,
Abgent). HPV16 E2 has three residues with more than 80% probability
to be sumoylated: K172, K292, and K351 (Fig. 4A and Table 1). K172 is
located in the transactivation domain (TAD) of E2, and K292 and K351
map to the DNA-binding domain (DBD) of E2. To test the ability of
these mutant E2 proteins to be sumoylated, HeLa cells were
transfected with each of these mutants together with SUMO3 and
Ubc9. Under these conditions, all of the mutants were expressed at
levels comparable to the wild-type E2 (Fig. 4B, upper panel), but only
the K292R mutant of 16E2 lost the ability to be sumoylated while the
K172R and K351R mutants did not. Furthermore, of these 3 potential
sites, only the K292 position is absolutely conserved as a high
probability sumoylation site in all twelve high-risk HPV E2 protein
sequences examined (not shown). In contrast, predicted sumoylation
sites at K172 or K351 are present in only 7 of 12 and 10 of 12 high-risk
E2 proteins, respectively. Based on these results, we believe that K292
is the primary sumoylation target for 16E2, and that it is likely that all
the high-risk E2 proteins could be sumoylated at the comparable
position.with 0.5 μg of neomycin resistant plasmid (pcDNA3.1) together with 3 μg of plasmids
tion for 3 weeks. After ﬁxing and staining the cells, the number of colonies was counted
e plate from one of the three independent experiments. The graph in lower panel shows
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the sumoylation site lysine residue
Sumoylation has been described as an important regulator of the
transcriptional activity for numerous cellular and viral transcription
factors. Typically, transcription factor mutants lacking the sumoyla-
tion site show altered transcriptional activity compared to their
wild-type counterpart. It is well documented that introducing E2
into HeLa cells causes cellular growth inhibition and reduced colony
formation due to E2-dependent transcriptional repression of the
HPV18 P105 promoter, which regulates E6 and E7 expression levels
(Dowhanick et al., 1995; Francis et al., 2000; Hwang et al., 1993;
Thierry and Yaniv, 1987). Consequently, to investigate the effect of
sumoylation on E2 transcriptional repression activity, we compared
the wild-type E2 protein with the sumoylation-defective K292R
mutant E2 protein in the HeLa colony formation assay. In this assay,
both 16E2WT and 16E2K292R markedly inhibited colony formation
to an identical level (Fig. 5). Furthermore, compared to the large and
numerous neomycin-resistant colonies formed in the absence 16E2,
wild-type and the K292R mutant 16E2 not only reduced the number
of colonies formed, but also decreased the size of these colonies.
Thus, 16E2K292R could not be distinguished from wild-type E2 in
this long-term assay.
As an alternative to the HeLa assay, the activities of 16E2WT and
16E2K292R were compared in short-term transient reporter assays.
To investigate the contribution of sumoylation to E2 transactivation
activity, we examined the activity of wild-type and K292R HPV16
E2 in C33A cells using an E2-activated reporter vector (p6xE2BS-
Luc) with 6 E2 binding sites. The ability of 16E2WT to transactivate
this 6xE2BS-Luc reporter vector was 10.2-fold over basal level, but
the transactivational ability of 16E2K292R was reduced to only 5.7-
fold over basal level (Fig. 6A, left panel). This 44% reduction in
activity for the E2K292R mutant was statistically signiﬁcant. For the
effect of sumoylation on the transcriptional repression ability of E2,
we also tested the response of both 16E2WT and 16E2K292R in
C33A cells using pHPV18LCR-Luc, an HPV18P105 promoter-drivenFig. 6. The sumoylation defectivemutant of HPV16 E2 shows reduced transcriptional activity.
β-Gal together with 0.55 μg of either 16E2WT,16E2K292R, or empty parental vector (CMV). p
with 0.2 μg of HPV18LCR-Luc and 0.1 μg of pSV-β-Gal together with 5 μg of either 16E2WT,16E
described in Materials and methods, and the data represent the average number from three
with a p-valueb0.005. (B) Expression of 16E2WT or 16E2K292R in the extracts from part (Aluciferase plasmid (Schweiger et al., 2007). 16E2WT reduced activity
of the p105 promoter by 50%, while 16E2K292R reduced this
activity only by 30% (Fig. 6A, right panel), which was again statis-
tically signiﬁcant. Western blot analysis (Fig. 6B) demonstrated that
the level of 16E2K292R was equal to that of 16E2WT under these
conditions, indicating that the reduced transcriptional activity of
16E2K292R on both promoters was not due to differences in protein
expression.
The K292R mutation does not affect E2 DNA binding or localization
Due to the location of K292 in the DBD of HPV16 E2, it was possible
that the K292R mutation affected DNA binding by the mutant protein,
and that a defect in this function accounted for the reduced
transcriptional activity. Based on the three-dimensional structure of
16E2, K292 is directly involved neither in DNA contact nor in
dimerization (Hegde and Androphy, 1998), but mutation of this
residue still might have subtle effects on structure that resulted in
reduced DNA interaction capacity. To conﬁrm that the K292R
mutation did not impede the binding of 16E2 to the E2-speciﬁc
sequence (E2BS), we performed an EMSAusing GST, GST-16E2WT, and
GST-16E2K292R. The amount of puriﬁed GST-16E2WT and GST-
16E2K292R used in EMSA was ﬁrst measured by Western blot of
serially diluted samples (Fig. 7A), and then 1× of both puriﬁed E2
proteins was used to carry out the gel mobility shift assay (Fig. 7B).
When adjusted for protein levels, 16E2WT and 16E2K292R possessed
equal ability to bind to the E2BS oligo, and no E2 binding was detected
for the control oligo. The absence of retarded bands with the GST
sample indicated that the binding with GST-E2 was due to the 16E2
proteins and not the GST moiety. Further titration over a range of E2
concentrations showed no signiﬁcant difference between wild-type
and mutant E2 protein (not shown). From these results we conclude
that the K292R mutation is unlikely to negatively affect the
dimerization or the DNA binding ability of 16E2. Whether or not
sumoylation of E2 alters its DNA binding properties has not yet been
determined.(A) Left panel, C33A cells were transfectedwith 0.2 μg of p6xE2BS-Luc and 0.3 μg of pSV-
cDNAwas used to adjust the total DNA to 2.4 μg. Right panel, C33A cells were transfected
2K292R, or empty parental vector (CMV). Luciferase and ß-gal assays were performed as
independent experiments. The difference in transcriptional activity (⁎) was signiﬁcant
) was detected by Western blotting with an anti-16E2 antibody.
Fig. 7. DNA-binding ability and intracellular localization of HPV16 E2. (A) The amount of
puriﬁed GST-16E2WT (left panel) and GST-16E2K292R (right panel) used in the EMSA
was quantitated by Western blot of serially diluted E2 samples. (B) The electrophoretic
mobility shift assay (EMSA) was performed as described in Materials and methods.
Brieﬂy, 50 ng of each protein (GST, GST016E2WT, and GST16E2K292R) was assayed with
5 fmol of either the 32P-labeled E2 binding site oligonucleotide (E2BS) or a 32P-labeled
control oligonucleotide (CS) lacking an E2BS. The Buffer lanes had no protein added. The
free oligonucleotides are indicated with the arrowhead and the 16E2-bound DNA is
indicated with the arrow. (C) Fluorescent images showing the localization of wild-type
(an upper panel) and K292R mutant (a lower panel) EGFP-16E2 proteins in HeLa cells.
HeLa cells were transfected with either EGFP-16E2WT or EGFP-16E2K292R, and the E2
proteins were visualized by ﬂuorescent microscopy at 48 h post-transfection.
334 Y.-C. Wu et al. / Virology 378 (2008) 329–338Sumoylation is also known to affect cellular localization of target
proteins (Wilson and Rangasamy, 2001), and lysine 292 is just
upstream of the nuclear localization sequence of HPV16 E2
(Klucevsek et al., 2007). Hence, it was important to determine if
the subcellular localization of 16E2 was inﬂuenced by the K292R
mutation which could result in differences in transcriptional
activities. We performed ﬂuorescent microscopy of both 16E2WT
and 16E2K292R in HeLa cells (Fig. 7C). The pattern of the EGFP-
16E2WT (Fig. 7C, upper panel) mirrored that of the lysine 292 to
arginine mutant (Fig. 7C, lower panel). Both WT and K292R mutant
E2 proteins were predominantly nuclear and partly cytoplasmic, and
there was no apparent difference in the distribution of these two
types of 16E2 protein. Thus, since mutation of the sumoylation target
site does not inﬂuence the subcellular localization of HPV16 E2, it
appears that sumoylation is not required for nuclear entry of E2.
Furthermore, since the K292R mutation does not appear to inﬂuence
the DNA binding activity or subcellular localization of 16E2, the most
likely explanation for the reduced transcriptional activity of theK292R mutant is that sumoylation has a modest regulatory role in E2
transcriptional activity.
Discussion
The life cycle of papillomaviruses is closely linked to the diffe-
rentiation process of epithelial keratinocytes (Longworth and
Laimins, 2004). One of the critical early viral proteins is the
multifunctional E2 protein which acts as a replication initiation
factor (Demeret et al., 1995; Ferguson and Botchan, 1996; Sakai et al.,
1996), has a genome segregation function (Bastien and McBride,
2000; Voitenleitner and Botchan, 2002; You et al., 2004), and is a
transcriptional regulatory protein (Hirochika et al., 1988; Phelps and
Howley, 1987; Spalholz et al, 1985; Stenlund and Botchan, 1990; Tan
et al., 1994). Recently we showed that sumoylation, a post-
translational modiﬁcation that often regulates cellular transcription
factor activity (Verger et al, 2003), was upregulated during
keratinocyte differentiation (Deyrieux et al., 2007). This observation
raised the possibility that E2 proteins might also be regulated by
sumoylation during keratinocyte differentiation. Using an in vitro
GST pull-down assay, we conﬁrmed that Ubc9, the SUMO conjugat-
ing enzyme, speciﬁcally interacts with BPV1 and HPV E2 proteins.
We further demonstrated that E2 proteins not only bind to Ubc9, but
are also substrates for sumoylation in vitro and in vivo. The
sumoylation of E2 appears to be through an authentic isopeptide
linkage as the SUMO moiety could be removed by the SUMO-speciﬁc
proteases, Ulp1 (in vitro) or SENP1 (in vivo). Sumoylation of 16E2 was
observed in vivo with SUMO1, SUMO2, or SUMO3, with no apparent
difference in efﬁciency under these over-expression conditions. The
precise differences between SUMO1 and the SUMO2/3 family in
regulating the functions of target proteins are unknown, however,
some cellular proteins are preferentially sumoylated with SUMO1
versus SUMO2/3 while others appear to be modiﬁable by either
SUMO family (Rosas-Acosta et al., 2005a,b). In keratinocytes we ob-
served that it is primarily expression of the SUMO2/3 family that
increases during keratinocyte differentiation (Deyrieux et al., 2007),
suggesting that SUMO2/3 modiﬁcation of E2 proteins may actually
be the biological event.
One of the technical challenges for sumoylation studies is the
typically low level of a sumoylated protein compared to its
unmodiﬁed form. For most known sumoylated proteins, sumoyla-
tion can be detected in vivo only after over-expression of SUMO or
of SUMO plus Ubc9, and this was true for E2 as well, as no
sumoylated forms were detected in the absence of over expression
of the sumoylation components. In addition, we found that adequate
detection of the sumoylated E2 species required treatment of the
cells with a proteasome inhibitor. It is well established that E2
proteins have short half-lives, and for BPV1 E2 the PEST sequence
targets it for proteasomal degradation (Penrose and McBride, 2000).
Likewise, HPV18 E2 has been shown to undergo proteasomal
degradation (Bellanger et al., 2001), and this is likely a general
feature of E2 proteins. Several proteasome inhibitors have been
shown to stabilize E2 proteins (Bellanger et al., 2001; Penrose and
McBride, 2000), and we found that ALLN treatment dramatically
increased the level of E2 protein after transient transfection (not
shown). Only when the E2 levels were enhanced with ALLN was
there sufﬁcient signal for detecting the sumoylated form of E2. This
requirement for both exogenous expression of the sumoylation
components and stabilization of E2 with a proteasomal inhibitor
probably accounts for the failure of sumoylated E2 to be observed
previously. While these conditions may seem extreme and could
raise doubts about the biological signiﬁcance of E2 sumoylation,
these conditions are not in fact signiﬁcantly different from those
used in many sumoylation studies. Furthermore, while many
sumoylated cellular transcription factors have only a small fraction
of their total protein in the sumoylated form, even under over-
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demonstrates a measurable effect on function. Similarly, mutation
of the SUMO addition site in 16E2 resulted in a signiﬁcant decrease
in transcriptional activity on two types of promoters (Fig. 6 and
discussed further below), supporting the likelihood of endogenous
and functional sumoylation at this site.
Our mutational analysis of HPV 16 E2 identiﬁed lysine 292 in
HPV16 E2 as the predominant site of sumoylation. The two other
highly predicted sumoylation sites in 16E2, lysines 172 and 351, were
tested, and neither of them appeared to be a target for sumoylation.
However, we are unable to exclude the possibility of minor
modiﬁcation by SUMO at these two lysines or other sites on E2
which might be below detectable limits by western blot and yet
could have functional consequences. It should be noted, however,
that a lysine within a potential sumoylation motif is conserved in the
position homologous to HPV 16E2 residue 292 in all high-risk E2
proteins, while there is not complete conservation of the predicted
sumoylation sites at residues 172 and 351 (not shown). The complete
conservation of the 292 sumoylation site suggests that sumoylation
at lysine 292 may be a critical regulatory modiﬁcation for all E2
proteins in this group. In contrast, the low-risk HPV E2 proteins also
have predicted sumoylation sites, though not always at the lysine
292 equivalent. Thus, sumoylation of K292 may play a unique role in
regulation of high risk E2 functions.
Sumoylation is well known to modulate the activity of numerous
transcription factors, so its effects on E2 transactivation were
investigated. We found that the K292R mutant, which was not
sumoylated, had reduced transactivation activity compared to wild-
type 16E2. Since this mutant was not deﬁcient in expression, speciﬁc
DNA binding, or in subcellular localization, we conclude that the
reduced transcriptional activity of 16E2 K292R is most likely caused by
its inability to be sumoylated; these results indicate that the
transactivation activity of E2 is enhanced by sumoylation. While
sumoylation has commonly been shown to reduce transactivational
activity (Gill, 2005), there are several well-characterized examples of
enhanced transcriptional activity by sumoylation, including Oct4 (Wei
et al, 2007), HSF1 (Hong et al., 2001), and HSF2 (Goodson et al., 2001),
though the mechanism of activation remains undeﬁned. The transac-
tivational activity of E2 proteins has been shown to bemediated by the
cellular Brd4 protein (Ilves et al., 2006; McPhillips et al., 2006;
Schweiger et al., 2007; Schweiger et al, 2006; Senechal et al., 2007;
Wu et al., 2006). Blocking the binding of E2 to Brd4 or knockdown of
Brd4 expression by hairpin RNA, both inhibit E2-dependent transcrip-
tional activation. Interestingly, Brd4 displays multiple predicted sites
for sumoylation as well as potential SUMO binding motifs (data not
shown), raising the possibility that sumoylation of E2 could enhance
recruitment of Brd4 which would promote increased transcriptional
activity of E2. This potential effect through Brd4 as a mean by which
sumoylation stimulates the transcriptional activation of E2 proteins
will be investigated.
In addition to its transactivation activity, HPV E2 proteins act as
transcriptional repressors of the early promoter and thereby down-
regulate E6/E7 expression (Bernard et al., 1989; Steger and Corbach,
1997; Thierry and Yaniv, 1987). Our studies indicated that the K292R
mutant showed reduced repressive activity in a transient reporter
assay compared to wild-type E2 (Fig. 6A, right panel). While a similar
defect could not be demonstrated in the HeLa cell colony formation
assay, this could be due to the integrated state of the HPV18 LCR in
these cells compared to the episomal state of the LCR in the transient
reporter assay. Alternatively, the long-term colony assay may simply
be too insensitive to discriminate between relatively small differences
in E2 activity.
Two mechanisms have been proposed to explain SUMO-depen-
dent repression, sequestration of sumoylated transcription factors
into repressive nuclear subdomains (Ross et al., 2002) and recruitment
of co-repressors (Girdwood et al., 2003; Yang and Sharrocks, 2004).We did not observe any gross changes in subcellular localization
between the wild-type 16E2 and the K292R mutant form that could
not be sumoylated, but more detailed studies will be required to
assess possible subtle effects of sumoylation on E2 localization within
the nucleus. Effects of sumoylation on E2 interactions with other
factors have not yet been investigated, but seem likely. E2 has
numerous interaction partners, including a variety of transcription
factors which can be classiﬁed as basal/remodeling factors or speciﬁc
transactivators. TFIIB (Benson et al., 1997; Rank and Lambert, 1995;
Yao et al., 1998), TBP (Ham et al., 1994; Steger et al., 1995), AMF-1
(Breiding et al., 1997; Peng et al., 2000), p/CAF (Lee et al., 2002), and
p300/CBP (Lee et al., 2000; Muller et al., 2002) are all basal/
remodeling factors with known E2-association. It will be important
to determine whether the sumoylation of E2 protein impacts
recruitment or binding to these factors, resulting in functional changes
in chromatin structure and/or transcription. Additionally, E2 also
binds to speciﬁc transactivators, such as CEF (Lewis et al., 1999), C/EBP
(Hadaschik et al., 2003), Sp1 (Li et al., 1991; Tan et al., 1992), and YY1
(Lee et al., 1998) which are all involved in regulating either viral or
cellular gene expression. Whether or not the sumoylation of E2
inﬂuences these interactions and transcription from speciﬁc promo-
ters is also unknown. Lastly, tight regulation of E2 function during
keratinocyte differentiation is likely essential for normal progression
through the viral life cycle. As mentioned above, differentiation-
dependent increases in SUMO2/3 expression and in overall sumoyla-
tion have been observed in monolayer keratinocyte culture (Deyrieux
et al., 2007), and such changes could increase the ratio of sumoylated
to unsumoylated E2 and modulate E2 transcriptional activity.
Thorough understanding of the contribution of sumoylation to
regulation of E2 transcriptional activity should provide new insight
into viral reproduction, papillomavirus pathogenesis, and the host-
viral interplay. In addition, the discovery of sumoylated E2 offers a
potential new target for development of antiviral agents as prevention
of sumoylation might disrupt the viral vegetative cycle.
Materials and methods
Plasmids
Plasmids utilized in this study were generously provided by the
following: pET-18E2, Dr. F. Thierry; pSG5/HA-11E2 andpSG5/HA-16E2, Dr.
S.M. Huang; pTE1E2S1 and pTE1E2S2, Dr. H. Saitoh; pWEB-16E2 and
pGEX-16E2, Dr. K. Gaston; p6xE2BS-Luc, Dr. F. Stubenrauch; pHPV18LCR-
Luc, Dr. P. Howley; pEGFP-SENP1WT and pEGFP-SENP1C599A, Dr. T.
Nishida; pcDNA3.1/HA-SUMO2, pcDNA3.1/HA-SUMO3, and the GST-
SAE1/SAE2 expression plasmid, Dr. Ronald T. Hay. The pRSET-BPV1 E2
plasmid (Leng, et al,1997), thepRSET-SUMO1plasmid (Rosas-Acosta et al.,
2005a, b), and the pcDNA5/FRT/TO/His-S-SUMO1 and pcDNA5/FRT/TO/
HA-Ubc9 plasmids (Rosas-Acosta et al., 2005a, b) have all been described
previously.
Mutagenesis
All mutants were all constructed with the QuickChange poly-
merase chain reaction-based mutagenesis kit (Stratagene). The
pEGFP-16E2K292R, pGEX-16E2K292R, and pWEB-16E2K292R
mutants were developed using the primers set: 5′-CTACACCC-
ATAGTACATTTACGAGGTGATGCTAATAC-3′/5′-GTATTAGCATCA-
CCTCGTAAATGTACTATGGGTGTAG-3′. The pWEB-16E2K172R and
pWEB-16E2K351R mutants were constructed using the primers 5′-
GGAATACGAACATATTTTGTGCAGTTTCGAGATGATGCAG-3′/5′-CTG-
CATCATCTCGAAACTGCACAAAATATGTTCGTATTCC-3 ′ and
5′-GGCAACGTGACCAATTTTTGTCTCAAGTTCGCATACCAAAAAC-3′/5′-
GTTTTTGGTATGCGAACTTGAGACAAAAATTGGTACCGTTGCC-3′ ,
respectively. The underlined sequences indicate the mutant codon.
All the mutants were conﬁrmed by sequencing.
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GST and GST-Ubc9 were expressed using the pGEX-5X-1-based
expression plasmids as previously described (Rangasamy and
Wilson, 2000). GST or GST-Ubc9 were transformed into the E. coli
BL21(DE3) strain while GST-16E2 and GST-16E2K292R were trans-
formed into Rosetta2 strain. Twelve ml of overnight cultures were
inoculated into 500 ml of 2XYT broth supplemented with 100 μg/ml
of ampicillin and incubated at 37 °C until reaching an OD600=0.6 to
0.8, followed by induction at 28 °C for 4 h with a ﬁnal concentration
of 0.5 mM isopropylthiogalactoside (IPTG). After collection, the cells
were resuspended in lysis buffer (phosphate buffered saline, pH 7.3,
5 mM phenylmethylsulfonylﬂuoride, 5 mM dithiothreitol, 15 mg
lysozyme). The lysate was kept on ice for 30 min followed by
sonication four times for 10 s at 36 W. Triton X-100 was then added
to the lysates to a ﬁnal concentration of 1%, and the lysates were
centrifuged at 10,000 ×g at 4 °C for 30 min. Then, the supernatant
was incubated with 600 μl of glutathione-Sepharose 4B beads
(Amersham Pharmacia Biotech) at 4 °C for 2 h. The glutathione-
Sepharose beads were washed four times with phosphate buffered
saline, pH 7.3. Puriﬁed proteins were eluted with elution buffer (20
mM L-reduced glutathione [Sigma], 100 mM Tris–HCl, pH 8.0,
120 mM NaCl). The proteins were then supplemented with glycerol
to a ﬁnal concentration of 10% and stored at −70 °C. The quan-
tiﬁcation of proteins was performed using the Bradford assay.
In vitro Ubc9 binding assay
The BPV1 E2, HPV11 E2, HPV16 E2, and HPV18 E2 proteins were
expressed from the pRSET-BPV1E2, pSG5/HA-11E2, pSG5/HA-16E2,
and pET-18E2 plasmids, respectively, using the T7-coupled rabbit
reticulocyte lysate system in the presence of [35S] methionine
according to the manufacturer's instructions (Promega). For the GST
pull-down assay, 2 to 8 μg of GST alone or GST-Ubc9 fusion proteins
were pre-incubated with 26.7 μl of glutathione-Sepharose beads with
agitation for 1 h at room temperature in 0.5 ml of binding buffer
(10 mM Tris–HCl, pH 7.4, 150 mMNaCl, 5 mMMgCl2, 0.05% Tween 20,
0.5% bovine serum albumin). 3 μl of 35S-labeled protein were then
added to the beads, and incubationwas continued for another 2 h. The
beads were washed twicewith binding buffer and another three times
with wash buffer (10 mM Tris–HCl, pH 7.4, 5 mMMgCl2, 0.05% Tween
20) supplemented with 200 mM NaCl, 300 mM NaCl, and 150 mM
NaCl, respectively. Labeled protein bound on the beads was recovered
by heating at 95 °C in 6 μl of SDS-sample buffer (150 mM Tris–HCl, pH
6.8, 12% SDS, 30% glycerol) and was analyzed by SDS-polyacrylamide
gel electrophoresis. Radiolabeled bands were visualized by autoradio-
graphy, and the results were quantitated by densitometry.
In vitro sumoylation assay
All sumoylation components were expressed and puriﬁed as
described previously (Rosas-Acosta et al., 2005a,b). Brieﬂy, SAE2 and
SAE1 were co-expressed and co-puriﬁed by using thrombin digestion
to release the bound enzyme from glutathione-Sepharose 4B beads;
Ubc9 was similarly puriﬁed using elution by Factor Xa digestion. His-
SUMO1 was puriﬁed through Ni2+-NTA-Agarose resin (QIAGEN). In
vitro sumoylation assays were carried out by incubating the
substrate proteins (2 μl of 35S-labeled in vitro translated E2 proteins),
with or without 1.5 μg of SAE2/SAE1, 0.5 μg of Ubc9, and 4 μg of
SUMO1. All the reactions were performed for 90 min at 30 °C in a
ﬁnal buffer volume of 25 μl containing 50 mM Tris pH 8.0, 5 mM
MgCl2, 5 mM ATP, and 0.5 mM DTT. 9 μl of SDS-sample buffer were
added to each sample to stop the reaction, and then the samples
were incubated at 95 °C for 7 min. These samples were analyzed on
an SDS-PAGE gel, and processed as described for the in vitro binding
experiments.Escherichia coli SUMO modiﬁcation/expression system
pTE1E2S1 or pTE1E2S2 were introduced into the BL21(DE3) strain,
and single colonies of each were used to generate the pTE1E2S1 or
pTE1S2 competent cells. The pET-18E2 or pRSET-BPV1E2 plasmids,
which encode the substrate proteins, were then transformed into
these pTE1E2S1/S2 competent cells by heat shock. A single colony was
selected and transferred to 12 ml of Luria Bertani (LB) media
containing 50 μg/ml of chloramphenicol and 100 μg/ml of ampicillin.
Bacterial cultures were incubated at 37 °C with shaking until reaching
an OD600=1.0, and then IPTG was added to the culture to a ﬁnal
concentration of 0.5 mM. After incubation for 8 h at 23 °C, 1 ml of the
bacterial culture was collected by centrifugation and the pellet was
resuspended in 100 μl of TE (10 mM Tris–HCl, pH 7.4, 1 mM EDTA, pH
8.0) buffer. The resuspended cells were lysed by addition of 100 μl of
SDS-sample buffer. After passage through a 26-gauge syringe, the
samples were denatured at 95 °C for 7 min. 20 μl of each sample were
analyzed by Western blotting.
Cell culture, transfection, and luciferase assay
HeLa cells were maintained and grown in Dulbecco MEM (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 44 mM of
sodium bicarbonate. C33A cells were maintained and grown in DMEM
supplemented with 10% FBS and 17.9 mM of sodium bicarbonate. Both
cell lines were maintained at 37 °C and 5% CO2 in a humidiﬁed
incubator. For HeLa cell transfections, 6×105 cells were plated in 6-
well plates the day before transfection. The transfections were
performed using a total of 6 μg of DNA and 6 μl of Lipofectamine
2000 (Invitrogen) according to the supplier's recommendations. Two
days after transfection, the HeLa cells were collected by addition of
500 μl of boiling SDS-sample buffer. These samples were passed
through a 26-gauge syringe and denatured at 95 °C for 7 min. Then,
30 μl of each sample were resolved by SDS-PAGE followed byWestern
blot analysis. For the Luciferase assay, 1.2×106 C33A cells were plated
in 12-well plates the day before transfection. The p6xE2BS-Luc or
pHPV18LCR-Luc plasmids were co-transfected with the pSV-β-
Galactosidase control vector (Promega) and the E2 plasmids (wild-
type or K292R mutant) using Lipofectamine 2000. C33A cells were
collected two days after transfection using 200 μl of Luciferase Cell
Culture Lysis Reagent (Promega), and the Luciferase assay was
performed using the Luciferase Assay System according to the
manufacturer's instructions (Promega). The β-galactosidase assay
was performed with ONPG as the substrate and was read at OD420.
Luciferase activity was measured as luminescence using a Tecan
Inﬁnite M200 plate reader, and the luciferase values were normalized
using the β-galactosidase activity. The transcriptional activities of the
wild-type and mutant E2 proteins were compared using the Student's
t test.
Western blot
Western blotting was performed according to standard proce-
dures using the following primary antibodies: mouse anti-His
(1:10000, Santa Cruz), mouse anti-HPV16 E2 (1:1000, Santa Cruz),
rabbit anti-Ubc9 serum [1:1000, (Deyrieux et al., 2007)], and mouse
anti-GFP (1:5000, Santa Cruz). Brieﬂy, the protein samples were
resolved on SDS-PAGE and were then transferred to Millipore
0.45 μm Immobilon-P membranes. After transfer, the membrane
was blocked in TTBS (150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 0.05%
Tween 20) with 5% non-fat milk for 30 min. The membrane was
then incubated with the indicated primary antibodies and the
corresponding HRP-conjugated secondary antibodies (Santa Cruz).
The membranes were treated with the Western Lightning Chemilu-
minescence reagent (PerkinElmer Life and Analytical Sciences) or
Immobilon Western reagent (Millipore) and exposed to X-ray ﬁlm.
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Gel shift assays were performed as described previously (Gonzalez
et al., 2000). Brieﬂy, 2 to 5 fmol of radiolabeled oligonucleotide and
20 ng pUC18 DNA were incubated with 50 ng of puriﬁed GST, GST-
16E2, or GST-16E2K292R in 10 μl of EMSA reaction buffer (20 mM
potassium phosphate, pH 7.0, 100 mM NaCl, 1 mM EDTA, 0.1% NP-40,
10% glycerol, 5 mM DTT, 0.07% BSA). Oligonucleotides E2BSU (5′-
CGGTACGGGAACCGCACCCGGTAC-3′) and E2BSL (5′-CGGTACG-
TACCGGGTGCGGTTCCC-3′) were annealed to form a double-stranded
DNA containing a consensus papillomavirus E2 binding site. Oligonu-
cleotides CU (5′-CGGTACGGGACTGCCCGCGAACAC-3′) and CL (5′-
CGGGACGTGTTCGCGGGCAGTCCC-3′) were annealed to form a control
double-stranded DNA with a similar GC content, but without an E2
binding sites. Both annealed oligonucleotides were radiolabeled as
previously described (Gonzalez et al., 2000). Puriﬁed GST-E2 protein
samples were incubated with the radiolabeled oligonucleotides for
30 min at 25 °C and were then electrophoresed on 8% nondenaturing
polyacrylamide gels in 0.5× Tris-borate-EDTA (TBE) buffer (pH 7.5).
Protein quantiﬁcation was carried out using densitometry after
Western blotting of serially diluted samples.
Fluorescence microscopy
HeLa cells were cultured in 6-well plates with 6×105 cell per well.
6 μg of EGFP-16E2WTor EGFP-16E2K292R DNAwere used to transfect
the HeLa cells using Lipofectamine 2000. Forty-eight h after transfec-
tion, cells were washed with cold phosphate buffered saline (PBS) and
ﬁxed with 2% paraformaldehyde. After mounting the cells with
toluene, cells were visualized by ﬂuorescent microscopy using an
Olympus LX70 microscope, and the images were captured digitally
using a Qcolor3 camera (Olympus).
Colony reduction assay
HeLa cells were cultured in 6-well plates with 6×105 cell per well.
The cells were co-transfected with a neomycin plasmid together with
either pcDNA5, pWEB-16E2WT, or pWEB-16E2K292R. At 24 h after
transfection, cells were split and cultured in triplicate and were
maintained for 3 weeks in growth medium supplemented with G418
(900 μg/ml). At 3 weeks, the cultures were washed twice with
phosphate-buffered saline, ﬁxed with methanol, and stained with
methylene blue. The total number of neomycin-resistant colonies was
counted and averaged.
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